



Figure S1. Anti-VEGF agents and injection intervals for eyes in the 18-month **A)** BRO cohort (n=95 eyes) and **B)** ALT cohort (n=29 eyes). ALT, brolucizumab alternating with another anti-VEGF; BRO, brolucizumab only; VEGF, vascular endothelial growth factor.



B)




Anti-VEGF Therapy ranibizumab bevacizumab aflibercept brolucizumab

Figure S2. Mean change in **A)** injection intervals and **B)** CMT from baseline to Month 18 in the BRO and ALT cohorts.

ALT, brolicizumab alternating with another anti-VEGF; BRO, brolicizumab only; CI, confidence interval; CMT, central macular thickness; N, number of eyes; VA, visual acuity

A)



B)

